Author

P. W. Laird

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

A. D. Cherniack· 1 shared A. Johnson-Buck· 1 shared D. Heiman· 1 shared G. Getz· 1 shared J. F. Gainor· 1 shared J. Kim· 1 shared L. Dai· 1 shared M. Miller· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. D. Cherniack

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ultrasensitive amplification-free quantification of a methyl CpG-rich cancer biomarker by single-molecule kinetic fingerprinting

L. Dai, A. Johnson-Buck, P. W. Laird, M. Tewari, N. G. Walter

This paper develops an amplification-free method to quantify DNA methylation at the BCAT1 promoter with high sensitivity and specificity, enabling improved early detection of methylated cancer DNA biomarkers.

bioRxiv · Apr 6, 2024Bioengineering

High-resolution lung adenocarcinoma expression subtypes identify tumors with dependencies on MET, CDK4, CDK6, and PD-L1

W. Roh, Y. Geffen, M. Miller, S. Anand, J. Kim, D. Heiman, J. F. Gainor, P. W. Laird, A. D. Cherniack, National Cancer Institute Center for Cancer Genomics Tumor Molecular Pathology (TMP) AWG, G. Getz

The paper identifies five lung adenocarcinoma expression subtypes using consensus hierarchical clustering and finds subtype-specific dependencies on MET, CDK4, CDK6, and PD-L1, which could guide targeted therapies.

bioRxiv · Feb 20, 2022 · PreprintCancer Biology